Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye surgery device put to the test in 205 patients

NCT ID NCT06799156

Disease control Sponsor: Beaver-Visitec International, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study is testing a new device called Virtuoso for eye surgeries like cataract removal and vitrectomy. The goal is to make sure it is safe and works well. About 205 adults who need these surgeries will take part. The study will compare how often problems happen during surgery with this device versus what is already known from other devices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 205 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient scheduled for either cataract surgery (subgroup "cataract"), pars-plana vitrectomy surgery, regardless of the indication (subgroup "vitrectomy"), or vitrectomy combined with cataract surgery (subgroup "combined procedure")

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary or repeat vitrectomy (only applicable to patients scheduled for vitrectomy or combined procedure) * Patients aged ≥ 18 years * Willing and able to provide written informed consent for participation in the study * Willing and able to comply with scheduled visits and other study procedures. Exclusion Criteria: * Patients aged \< 18 years * No post-operative 90 days visit is anticipated * Patients requiring or having already had scleral buckling * Patients with ocular comorbidities affecting surgical view including corneal opacities or scar * Pre-operative endothelial cell count \<1500 cells/cm2 (only applicable to patients considered for the cataract subgroup or the combined surgeries subgroup) * Advanced and secondary glaucoma * History of intraocular inflammation * Untreated diabetes * Microphthalmos or macrophthalmos * Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial. * Post-Traumatic eye * Subluxated lens * Morganian cataract * Weak zonules: zonuli lysis or zonula laxa manifest * Pregnant or nursing females

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract Vitrectomy Vitrectomy operation under general anesthesia

Contacts and locations

Locations

  • Ludwig Maximilian University of Munich

    Munich, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.